Medication info
Nexera Tablet 20mg (Esomeprazole Magnesium Trihydrate)

Nexera Tablet 20mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
(Ltd) White Life Science
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201601786 · Approved 2016.04.05 · Insurance code 625201280

Summary

Main use
Treatment and prevention of acid-related disorders, gastrointestinal disturbances associated with anti-inflammatory analgesics, and ulcers (including those associated with Helicobacter pylori and rebleeding)
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Antibiotic combination therapy for Helicobacter pylori eradication: Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug treatment Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection: Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Do not exceed a dose of 20 mg of this medicine in patients with severe hepatic impairment. Elderly patients: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
(Ltd) White Life Science

Efficacy & effects

Treatment and prevention of acid-related disorders, gastrointestinal disturbances associated with anti-inflammatory analgesics, and ulcers (including those associated with Helicobacter pylori and rebleeding)

  • Gastroesophageal reflux disease
  • reflux esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcer
View approved original text

This medicine is used for the treatment and prevention of gastroesophageal reflux disease, reflux esophagitis, and recurrence prevention. It also helps with the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It is effective for the treatment of gastric ulcers and prevention of recurrence related to the relief of upper gastrointestinal symptoms caused by non-steroidal anti-inflammatory drugs. It is used for the treatment of Zollinger-Ellison syndrome and is utilized for maintenance therapy to prevent bleeding due to gastric or duodenal ulcers. Overall, it is a medicine that helps treat and prevent various symptoms and diseases related to gastrointestinal disorders.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Antibiotic combination therapy for Helicobacter pylori eradication: Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical trials exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug treatment Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection: Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience with administration to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Do not exceed a dose of 20 mg of this medicine in patients with severe hepatic impairment. Elderly patients: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Adolescents aged 12 years and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms may be controlled by administering 20 mg once daily. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medicine should not be used in certain patients. For example, those who are allergic to this medicine or its ingredients, or have had hypersensitivity reactions to similar classes of drugs should not take it. Additionally, patients taking certain antibiotics or antivirals, those with heart-related diseases, or those who are breastfeeding should avoid this medicine. This medicine contains Yellow No. 5 dye, so those with allergies or hypersensitivity to this ingredient should take caution when using it. Various adverse reactions may occur during use, and if there are changes in physical condition such as headaches, dizziness, abdominal pain, rash, muscle pain, or blood disorder symptoms, immediate consultation with a doctor is necessary. In particular, if muscle pain or weakness worsens, it may indicate a serious side effect called rhabdomyolysis, so careful observation is required. This medicine inhibits gastric acid secretion to help treat gastrointestinal diseases, but long-term use may increase the risk of infection due to bacterial overgrowth in the stomach. Additionally, long-term use for more than a year may increase the risk of fractures; therefore, regular monitoring of patients at risk for osteoporosis is recommended. This medicine can interact with other medications, so dosage adjustments are necessary especially when taken with anticoagulants, antibiotics, antivirals, antiepileptics, etc. Pregnant or breastfeeding individuals should consult with a doctor regarding the use of this medication, and it is safest not to take it while breastfeeding. There is no specific antidote for overdose, so if symptoms occur, immediate hospital visit for appropriate treatment is required. Finally, keep this medicine out of reach of children, and do not transfer it to another container for safe storage.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylaxis, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions accompanied by eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reactions, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, flu-like symptoms, generalized edema, leg edema, lethargy, pain, stiffness, flushing, hypertension, tachycardia, thyroid goiter, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal dysmotility, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormality, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, anorexia, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, olfactory disturbances, loss of taste, taste disorders, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infections, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcers, esophageal varices, gastric ulcers, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric mucosal polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to prevent air and moisture from entering, and should be kept at room temperature between 1 degree and 30 degrees. Storing it this way can help maintain the medicine's effectiveness for a longer time.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.